� OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated EDC solutions for clinical trials, today announced that the caller is providing EDC package and services for a Phase II trial in BRCA 1/2 and HNPCC patients sponsored by the Tucson Arizona based biotechnology, Systems Medicine LLC (SML). SML initially began its relationship with OmniComm through OmniComm's CRO Preferred Program� and then selected OmniComm as its EDC seller of choice for their Phase II study.
"Our initial experience in on the job with OmniComm was very favorable and as a result we chose to use them in our next trial. We were impressed with their responsiveness and professionalism throughout the entire dialogue and written report build process," said Patrick Shannon, Ph.D., Senior Director Project Management for Systems Medicine LLC.
Systems Medicine, LLC (SML) develops oncology products by integrating prognostic cellular pharmacogenomics ("genomics") with world-class clinical and regulatory expertise. This allows SML to develop patient-selective therapies by defining the context of use of vulnerability of cancer and treating only those patients nigh likely to respond to specific drugs or drug combinations. For more information on SML and the products that SML has in developing, please visit http://www.systems-medicine.com.
"Research organizations are looking at at EDC as a strategic imperative to serve maximize their investments in today's highly competitive clinical research environs," said Stephen Johnson, COO of OmniComm. "OmniComm is privileged to be partnering with companies like SML that ar delivering cutting off edge crab treatments to the marketplace. It gives us outstanding satisfaction to know that our TrialMaster EDC solution helps to speed up that serve."
About OmniComm
OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial enquiry. OmniComm's ontogeny base of satisfied customers is a direct result of the company's commitment to cede products and services that ensure ease of exercise, faster study build, simplicity of integration and better performance. OmniComm's client intuitive pricing example allows companies that cooking stove from little to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements around OmniComm's future expectations, including without restriction, future revenues and earnings, plans and objectives for the future operations, future agreements, succeeding economic carrying into action, operations and all other statements in this press release former than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but non limited to economic private-enterprise, governmental, contractual and technological factors poignant OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.
OmniComm
More info
